JA

Jun Axup

COO at E11 Bio, a neuroscience Focused Research Organization

San Francisco Bay Area

Invests in

Stages:

  • Min Investment:

    $250,000.00
  • Max Investment:

    $250,000.00
  • Target Investment:

    $250,000.00

Work Experience

2022

  • Chief Operating Officer

    2023

  • Director Of Partnerships

    2022 - 2023

    E11 Bio (http://e11.bio) is a non-profit Focused Research Organization developing next-generation technologies to accelerate neuroscience and improve human health. We are making single-cell brain circuit mapping a routine and accessible part of every neuroscientist’s toolbox. We are a part of Convergent Research (https://convergentresearch.org/) and supported by Schmidt Futures (https://www.schmidtfutures.com/).

2016 - 2022

  • Chief Science Officer & Partner, IndieBio

    2016 - 2022

    IndieBio (http://indiebio.co/) is the world's leading seed-stage life science accelerator. Based in San Francisco and New York City, our program trains scientists to become entrepreneurs to solve the most pressing issues in human and planetary health. Our 4-month program includes $525K funding, fully-equipped labs, and dedicated mentorship. During my tenure, we funded and advised over 170 biotech companies across all sectors. Notable alumni include: • food - Upside Foods, NotCo, The EVERY Company, Prime Roots, New Culture, Endless West • sustainable agriculture - Beeflow, NovoNutrients, Vertical Oceans • consumer biotech - Geltor, OneSkin, Sun Genomics • computational biology - Catalog Technologies, Gatehouse Bio • therapeutics - SyntheX, Prellis Biologics, Indee Labs • biomaterials - MycoWorks, Huue, Lingrove

  • Co-founder & COO

    2015 - 2016

    Next-generation multiplex proteomics profiling technology for precision medicine • Designed and performed proof-of-principle experiments • Managed lab operations and collaborations

2014 - 2015

  • Scientist, Biology Lead

    2014 - 2015

    Lab automation robotics startup to accelerate biological research • Biology and chemistry generalist for oligo synthesis and CRISPR/Cas9 products • Product development, optimization, troubleshooting, and experimental design • Lab robotics programming and operations; data and visualization in Python

2011 - 2014

  • Founder & CEO

    2011 - 2014

    Science toys for education and outreach • Designed and commercialized interactive DNA molecule plush toys • Managed overseas manufacturing and shipping logistics

2013 - 2014

  • Scientist, Protein Engineering

    2013 - 2014

    Biotech company pioneering cell-free synthesis technology for the development of antibody-drug conjugates, bispecific antibodies, and immuno-oncology drugs • Developed and performed high-throughput screening assays for antibody discovery • Biophysical characterization of antibodies and bispecific antibodies • Optimized cell-free synthesis for engineered antibody scaffolds • Performed protein conjugations

  • Graduate Researcher

    2008 - 2013

    Advisor: Peter G. Schultz • Developed in vitro and in vivo applications of genetically encoded unnatural amino acids • Synthesized site-specific antibody-drug conjugates and bispecific antibodies for selective treatment of cancer

2005 - 2008

  • Undergraduate Researcher

    2005 - 2008

    Advisor: Thomas J. Tolbert • Synthesized post-translationally modified peptides using biological and chemical approaches • Cloned and purified glycan and glycoprotein processing enzymes